Overview

Seroquel XR in Adults With Schizophrenia

Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally given, up to 600 mg once a day for 42 days.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Quetiapine Fumarate